RET and non-small cell lung carcinoma: This frequency is comparable to and marginally higher than the prevalence of the other non-EGFR actionable oncogenic driver mutations observed in NSCLC namely ROS1 (1%–2%), NTRK1/2/3 (1%), RET (1%–2%), BRAF (1%–5%) and ALK (5%–7%) [5, 6].